Herrmann N, Lanctôt K, Myszak M
Division of Geriatric Psychiatry, University of Toronto, Ontario, Canada.
J Clin Psychopharmacol. 2000 Feb;20(1):90-3. doi: 10.1097/00004714-200002000-00015.
Twelve patients with moderate to severe dementia and severe behavioral disorders were treated with open-label gabapentin (200-1,200 mg/day) for 8 weeks in a prospective case-series design. Patients were nonresponders to previous trials of neuroleptics. Behaviors were measured at 2-week intervals with the Neuropsychiatric Inventory (NPI), the Cohen-Mansfield Agitation Inventory (CMAI), and the Clinical Global Impression Scale (CGI). Gabapentin was generally well tolerated in this population. Although 42% of patients experienced adverse events such as gait instability and sedation, only two patients discontinued treatment prematurely because of adverse events. Average patient scores for the CMAI and the NPI remained unchanged after gabapentin. On the CGI, two patients were much improved, three were minimally improved, six were unchanged, and one was minimally worse. Gabapentin may have a role in treating a subgroup of dementia patients with severe behavioral disorders who have not responded to neuroleptics.
在一项前瞻性病例系列研究设计中，12名患有中度至重度痴呆及严重行为障碍的患者接受了为期8周的开放标签加巴喷丁治疗（200 - 1200毫克/天）。这些患者对先前的抗精神病药物试验无反应。每隔2周使用神经精神科问卷（NPI）、科恩 - 曼斯菲尔德激越量表（CMAI）和临床总体印象量表（CGI）对行为进行测量。加巴喷丁在该人群中总体耐受性良好。虽然42%的患者出现了如步态不稳和镇静等不良事件，但只有两名患者因不良事件提前停药。加巴喷丁治疗后，患者CMAI和NPI的平均得分保持不变。在CGI上，两名患者有显著改善，三名患者有轻微改善，六名患者无变化，一名患者有轻微恶化。加巴喷丁可能在治疗对抗精神病药物无反应的严重行为障碍痴呆患者亚组中发挥作用。
